Skip to main content

Table 1 Demographics, HIV disease and cardiovascular disease risks of patients at baseline

From: Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir

 

All

(n = 1067)

Stavudine

(n = 533)

Tenofovir

(n = 534)

Sex, female (n, %)

615 (57.6)

324 (60.8)

291 (54.5)

Age in years

35.3 (8.2)

35.5 (8.4)

35.0 (8.1)

Race (n, %)

  African

979 (91.8)

489 (91.7)

490 (91.8)

 Indian

86 (8.1)

43 (8.1)

43 (8.1)

 Other

2 (0.2)

1 (0.2)

1 (0.2)

Site (n, %)

 South Africa

600 (56.2)

300 (56.3)

300 (56.2)

 Uganda

381 (35.7)

190 (35.6)

191 (35.8)

 India

86 (8.1)

43 (8.1)

43 (8.1)

Marrieda (n, %)

139 (24.2)

69 (24.1)

70 (24.2)

Having childrena (n, %)

492 (85.9)

243 (84.1)

249 (87.7)

Employeda (n, %)

434 (76.0)

220 (76.1)

214 (75.9)

CD4+ cell count (cells/µL) (median, IQR)

206 (124–272)

206 (128–274)

206 (123–270)

Log HIV viral load (copies/mL)

11.26 (1.61)

11.34 (1.64)

11.18 (1.58)

History of hypertensionb (n, %)

59 (5.5)

28 (5.3)

31 (5.8)

History of diabetes mellitusb (n, %)

6 (0.6)

4 (0.8)

2 (0.4)

History of dyslipidemiab (n, %)

2 (0.2)

1 (0.2)

1 (0.2)

Current smokingc (n, %)

86 (15)

44 (15.3)

42 (14.7)

Current alcohol usec (n, %)

203 (35.4)

101 (35.1)

102 (35.8)

Current drug usec (n, %)

17 (3.0)

8 (2.8)

9 (3.2)

Systolic blood pressure (mmHg)

118.3 (13.2)

117.5 (13.5)

119.1 (12.8)

Diastolic blood pressure (mmHg)

72.9 (10.2)

72.5 (10.6)

73.4 (9.9)

Body mass index (kg/m2)

23.5 (4.4)

23.6 (4.6)

23.5 (4.2)

Follow-up time, median months, IQR

95.4 (95.0–95.7)

95.4 (95.0–95.7)

95.4 (95.1–95.8)

Total-C (mmol/L)

4.30 (1.02)

4.39 (1.11)

4.22 (0.93)

HDL-C (mmol/L)

1.32 (0.49)

1.37 (0.54)

1.27 (0.44)

LDL-C (mmol/L)

2.47 (0.86)

2.50 (0.93)

2.44 (0.79)

TG (mmol/L) (median, IQR)

1.00 (0.74–1.37)

1.00 (0.76–1.40)

0.98 (0.72–1.33)

Fasting glucose (mmol/L)

4.77 (0.97)

4.72 (0.64)

4.81 (1.20)

Fasting insulin (pmol/L) (median, IQR)

38.20 (25.70–55.56)

40.28 (27.09–57.64)

36.81 (24.31–54.17)

HOMA-IR (median, IQR)

1.13 (0.74–1.75)

1.18 (0.78–1.78)

1.09 (0.71–1.70)

Framingham risk score (%) (median, IQR)

1.86 (1.02–3.45)

1.90 (1.05–3.44)

1.82 (0.98–3.46)

  1. Values in mean with standard deviation unless otherwise specified
  2. HDL-C high density lipoprotein cholesterol, IQR interquartile range, LDL-C low density lipoprotein cholesterol, TG triglycerides; Total-C total cholesterol
  3. aData only available for the South African site, n=575 for marital status, n = 571 for employment status, n = 573 for having children
  4. bHistory or use of medication
  5. cData only available for the South African site, n=574 for current smoking, n = 573 for current alcohol use, n = 562 for current drug use
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us